[
    {
        "text": "[Music] welcome to the drive podcast i'm your host peter attea if you like this video please let me know by subscribing to the channel or visiting my website to become a member for more exclusive content yeah and we should make sure people understand some of the semantics so lpa is the gene that codes for april lipoprotein little a which then binds to an ldl and then turns an ldl from being just a garden variety ldl into an lp little a and i think once people understand that it becomes easier i think for us to communicate in this way so i'm going to restate that and i really want everyone to understand this so there's a gene lpa is the gene and this gene everybody has this gene but we have different variants of it and so a subset of the population and it varies considerably by ethnicity so african uh east asian also quite high down to caucasian and uh and and um as you mentioned chinese japanese etc so you're going to see different expressions of the apo lipo protein little a this apo lipoprotein little a which we'll talk a lot about and what it looks like and its structure and what its heterogeneity is all about but it wraps onto a low density lipoprotein and then it becomes kind of a supercharged load low density lipoprotein it becomes a particularly nefarious ldl and we're going to talk about all the reasons why it's not responsive to the same treatments etc so would you add anything to that like i don't want to make it too complicated yet but i want to make sure everybody understands when we talk about the lpa gene which is identified during the gwas experiments how the genotype",
        "start": "00:00:00",
        "duration": 211.531,
        "title": "Understanding semantics about Lp(a) and LDL | Peter Attia, M.D. & Benoît Arsenault, Ph.D."
    },
    {
        "text": "allows us to not know everything about the phenotype but we can start to get into trying to impute causal relationships and eventually we're going to talk of course about mendelian randomization where we can go even deeper anything you want to add to sort of the the basics of this no i think you've explained it perfectly peter maybe the only thing i would add is that part of the genetic heterogeneity among different people is the the apo lipoprotein a isoform size so people express different lpa isoforms some some are bigger than uh than the other and that that probably uh that well that actually plays an important part of the uh equation explaining why some people have a higher lp a little late than others i'm glad you reinforced that point because and this is going to get into a little bit of chemistry which i know some people will understand and some might not one of the big challenges here as you've now alluded to twice is the difficulty in measurement now when we look at something like apob and people who listen to this podcast a lot will be very familiar with apob we talk an awful lot about it one of the things we talk about is that by measuring the concentration of apob you can completely and accurately measure the concentration of the atherogenic particles the majority of which are ldl and the reason for that is twofold the first is that every ldl has one and only one apob 100 particle on it the second is that all apob's are the same size therefore they have a molar weight and by knowing the mass you know the number now there are i always like to point out two contrasts to this right the hdl particle by contrast has multiple apo a's on it and this is totally different",
        "start": "00:01:45",
        "duration": 223.75900000000001,
        "title": "Understanding semantics about Lp(a) and LDL | Peter Attia, M.D. & Benoît Arsenault, Ph.D."
    },
    {
        "text": "from apo little a so we're not going to talk about that other than to say it's apo big a and therefore you don't have a unique number and then of course with lp little a you have the problem that you raised which creates enormous challenges there is no molar weight for apo little a right this is this is the fundamental problem in the assay of trying to measure this thing exactly and uh we're really moving in the right direction in terms of getting the lpa measurement in nanomoles per per liter and there's more and more labs that are that are doing this and this is clearly the the way to go we have to move away from measurements in in milligrams per deciliter which is really influenced by the uh isoform size of lpa and the measurement in uh nanomolar will actually give you a much better sense of the number of lpa particles in the circulation and that's what we should be uh aiming at now will that require electrophoresis how will that actually be measured or will it use i mean it's going to be you measured through uh immunoturbidimetric assays so not by uh by nmr nmr can actually give you a a pretty good estimate of ldl particle number but you have to use antibodies to to to measure to measure lpa [Music] you",
        "start": "00:03:37",
        "duration": 185.93000000000006,
        "title": "Understanding semantics about Lp(a) and LDL | Peter Attia, M.D. & Benoît Arsenault, Ph.D."
    }
]